Antibody-based therapeutics have achieved great success in clinical cancer treatment, which bind to specific receptors overexpressed on cancer cells and induce cell apoptosis, such as cetuximab/panitumumab [targeting epidermal growth factor receptor (EGFR)], trastuzumab [targeting human EGFR 2 (HER2)] and conatumumab/lexatumumab/tumor necrosis factor-related apoptosis-inducing ligand [TRAIL, targeting death receptor 5 (DR5)]. Here, ERBB2 is linked to cancer.